HSBC Bank Plc : Form 8.5 (EPT/RI) - M P Evans Group PLC

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HSBC Bank Plc : Form 8.5 (EPT/RI) - M P Evans Group PLC

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: HSBC BANK PLC
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree   M P Evans Group PLC
(c) Name of the party to the offer with which exempt principal trader is connected: Kuala Lumpur Kepong Bhd
(d) Date dealing undertaken: 17 th November 2016
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? Yes - Kuala Lumpur Kepong Bhd

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received   Lowest price per unit paid/received  
  Ordinary Share   Purchase   5,450   703.38   702.00
  Ordinary Share   Sale     2,100   702.50     702.00

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (EUR)
  Ordinary Share   Swap   Closing a long position   500   703.38
  Ordinary Share   Swap   Opening a short position   2,850   703.38

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.         OTHER INFORMATION (a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"
    None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None
Date of disclosure: 18 th November 2016
Contact name: Ray Onrubia
Telephone number: 0207 088 2000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Rate and Betterment's Mortgage Play: Savings or Spin?

Updated Category News Views 151

So here’s the scoop: Rate just teamed up with Betterment on February 17, 2026, offering some pretty slick mortgage incentives for those sitting on at least $100K in their investment accounts. But let’s dig into the nitty-gritty before you start dreaming of that low-rate home loan. Betterment's Strategy: Solid Gains or Hype? The partnership aims to deliver discounted...

Continue Reading
UK Water Companies Gain Confidence After Regulatory Update

Updated Category News Views 253

Morgan Stanley Highlights UK Water Sector Improvements Investment risks surrounding listed UK water companies have significantly decreased following a key regulatory decision concerning water bill increases in England and Wales. According to analysts from Morgan Stanley, this development has created a more favorable landscape for investors in the sector. Key Insights From...

Continue Reading
SiLC Technologies Unveils Advanced Eyeonic Trace Scanner

Updated Category News Views 228

SiLC Technologies Introduces Eyeonic Trace Laser Line Scanner SiLC Technologies, a leader in the development of advanced integrated FMCW LiDAR solutions, recently announced an exciting new product: the Eyeonic Trace Laser Line Scanner. This state-of-the-art Class 1 Laser Line Scanner is engineered to achieve precise measurements of objects from distances of up to 10...

Continue Reading
Accord BioPharma Launches HERCESSI™ for Cancer Treatment

Updated Category News Views 94

Accord BioPharma Announces FDA Approval for HERCESSI™ Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has achieved a major milestone in cancer treatment with the FDA's approval of a new 420mg strength of HERCESSI™ (trastuzumab-strf). This biosimilar to Herceptin (trastuzumab) targets different types of HER2-overexpressing cancers, such as...

Continue Reading
Why Oklo Stock is Soaring This Week and What to Expect

Updated Category News Views 493

What’s Driving Oklo Inc’s Stock Surge? Oklo Inc (NYSE: OKLO) is making waves in the stock market as its shares witness impressive growth. Over the past month, the company has experienced a remarkable rally of approximately 60%. Investors are keen to learn about the driving forces behind this upward trend. Recent Positive Developments This recent surge can primarily be...

Continue Reading